Results 151 to 160 of about 618,162 (164)
ACS Medicinal Chemistry Letters, 2020 Following the impressive success of checkpoint inhibitors in the treatment of cancer, combinations of IDO1 inhibitors with PD-1/PD-L1 antibodies are in clinical development aiming to increase response rates.
Christoph Steeneck, Olaf Kinzel
exaly +2 more sources
Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?
Annual Review of Cancer Biology, 2020 Indoleamine-2,3 dioxygenase 1 (IDO1) contributes to tumor immunosuppression by enzymatically degrading tryptophan, which is required for T cell activity, and producing kynurenine.
Benoit van den Eynde +1 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
An updated patent review of IDO1 inhibitors for cancer (2018–2022)
Expert Opinion on Therapeutic Patents, 2022Pengfei Wang
exaly
A new series of IDO1 inhibitors derived from microbial metabolites
Phytochemistry Letters, 2023Xinhua Lu
exaly
Prediction of IDO1 Inhibitors by a Fingerprint‐Based Stacking Ensemble Model Named IDO1Stack
ChemMedChem, 2023Guixia Liu, Yun Tang
exaly
A patent review of IDO1 inhibitors for cancer
Expert Opinion on Therapeutic Patents, 2018Jae Eun Cheong, Lijun Sun
exaly
Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer
European Journal of Medicinal Chemistry, 2019Zhiyu Li, Qianming Du, Xi Feng
exaly